EGFR and non-small cell lung carcinoma: Approximately 60% of NSCLC patients with adenocarcinoma harbor oncogenic driver mutations, with the epidermal growth factor receptor (EGFR) mutation being the most commonly found and targetable driver mutation in NSCLC (3).